←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Antisense Oligonucleotides
Richard Geary
PhD
🏢Ionis Pharmaceuticals🌐USA
Executive Vice President of Development
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Richard Geary has led clinical development of antisense oligonucleotides at Ionis Pharmaceuticals, including pharmacokinetic characterization of multiple approved ASOs and cancer ASO clinical programs. His work has shaped the clinical pharmacology framework for the ASO field. He is a senior figure in ASO development.
Share:
🧪Research Fields 研究领域
ASO pharmacokinetics
ASO clinical development
cancer ASO trials
oligonucleotide pharmacology
RNase H ASO
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Richard Geary 的研究动态
Follow Richard Geary's research updates
留下邮箱，当我们发布与 Richard Geary（Ionis Pharmaceuticals）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment